Select Transactions
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
|
| Sale of Intrathecal business to |
|
|
$203 million
March 2017
|
|
| Microbiome partnership with |
|
|
$2.6 billion
($50 million upfront) January 2017
|
|
| Royalty-backed acquisition financing for undisclosed spec pharma |
|
|
$100 million
February 2016
|
Torreya is a leading strategic M&A advisor to global life sciences companies. MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales. MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations. MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals. MORE
The Future of the Global Pharmaceutical Industry
Torreya finds the global pharmaceutical industry is larger, innovating more rapidly, and likely to experience higher growth than previously thought.
- At approximately $5.4 trillion today, the pharma industry is around 30% larger than previously thought and is one of top five in the global economy by total value.1
- We estimate that the total revenue of the pharmaceutical industry will triple in real terms between 2017 and 2060.
- Major innovations will continue to drive the size and growth of the sector with positive implications for the health of the global population.
Click here for Report Executive Summary | Click here for full Future of Global Pharmaceutical Industry Report
1 Based on Torreya econometric model relating OECD estimates of future GDP growth to growth estimates for the pharmaceutical sector.